---
title: "KDL Biotech Ltd (KOPDRUGS) — Share Price, Financials & Analysis"
symbol: "KOPDRUGS"
company: "KDL Biotech Ltd"
canonical: "https://tapetide.com/stocks/KOPDRUGS"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:40:16.954Z"
---

# KDL Biotech Ltd (KOPDRUGS)

Canonical page: https://tapetide.com/stocks/KOPDRUGS

## Company

- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** kdlbiotech.com

## About

KDL Biotech Limited manufactures biotechnology based products. The Group specializes in Semi-synthetic Penicillins and related Enzymes.

## Latest Price

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.

## Growth Rates

| Metric | 1Y | 3Y |
| --- | --- | --- |
| net income growth | 12% | 6% |
| revenue growth | -100% | -22% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 5.12 | 0.99 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 5.41 | 2.23 | 0.7 | 0.44 | 1.17 | 0.31 | 0.3 | 0.34 |
| Operating Profit | -0.29 | -1.24 | -0.7 | -0.44 | -1.17 | -0.31 | -0.3 | -0.34 |
| OPM % | -5.66 | -125.25 | — | — | — | — | — | — |
| Other Income | 0.12 | 0.07 | 0.06 | 0.1 | 0.13 | 0.04 | 0.04 | 0.02 |
| Interest | 1.72 | 1.71 | 1.73 | 1.73 | 1.69 | 1.22 | 1.23 | 1.27 |
| Depreciation | 1.72 | 1.72 | 1.74 | 1.74 | 1.7 | 1.72 | 1.74 | 1.74 |
| Profit before tax | -3.61 | -4.6 | -4.11 | -3.81 | -4.43 | -3.21 | -3.23 | -3.33 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -3.61 | -4.6 | -4.11 | -3.81 | -4.43 | -3.21 | -3.23 | -3.33 |
| EPS in Rs | -1.5 | -1.91 | -1.71 | -1.59 | -1.84 | -1.34 | -1.34 | -1.39 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 6m | Sep 2007 18m | Sep 2008 | Mar 2010 18m | Mar 2011 | Mar 2012 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 55 | 165 | 57 | 38 | 28 | 26 | 0 |
| Expenses | 59 | 198 | 66 | 55 | 45 | 29 | 2 |
| Operating Profit | -3 | -33 | -9 | -17 | -16 | -2 | -2 |
| OPM % | -6 | -20 | -17 | -44 | -58 | -8 | — |
| Other Income | 1 | 42 | 6 | 15 | -11 | 1 | 0 |
| Interest | 5 | 13 | 10 | 3 | 7 | 7 | 5 |
| Depreciation | 4 | 10 | 7 | 12 | 22 | 9 | 7 |
| Profit before tax | -11 | -13 | -21 | -17 | -57 | -17 | -14 |
| Tax % | 0 | 0 | 0 | 0 | 14 | 0 | — |
| Net Profit | -11 | -14 | -21 | -17 | -64 | -17 | -14 |
| EPS in Rs | — | — | -8.79 | -7.08 | -26.76 | -7.16 | -5.91 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Sep 2007 | Sep 2008 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 17 | 17 | 24 | 24 | 24 | 24 |
| Reserves | -9 | -9 | 15 | -2 | -66 | -83 |
| Borrowings | 106 | 85 | 64 | 57 | 60 | 60 |
| Other Liabilities | 33 | 62 | 16 | 26 | 47 | 56 |
| Total Liabilities | 147 | 154 | 119 | 106 | 65 | 57 |
| Fixed Assets | 83 | 75 | 77 | 75 | 57 | 48 |
| CWIP | 0 | 0 | 6 | 4 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 64 | 79 | 36 | 27 | 8 | 9 |
| Total Assets | 147 | 154 | 119 | 106 | 65 | 57 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Sep 2007 | Sep 2008 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -1 | 3 | -6 | 3 | 2 | 7 |
| Cash from Investing Activity | 0 | -2 | -15 | -1 | 0 | 0 |
| Cash from Financing Activity | -1 | -2 | 22 | -3 | -2 | -7 |
| Net Cash Flow | -2 | -1 | 1 | -1 | 0 | 0 |
| Free Cash Flow | -1 | 1 | -21 | 2 | 1 | 7 |
| CFO/OP | 15 | -8 | 66 | -19 | -12 | -350 |

### Ratios

| Item | Mar 2006 | Sep 2007 | Sep 2008 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 210 | 50 | 7 | 1 | 4 | 0 |
| Inventory Days | 118 | 72 | 55 | 75 | 126 | 195 |
| Days Payable | 234 | 129 | 114 | 469 | 249 | 426 |
| Cash Conversion Cycle | 93 | -7 | -53 | -393 | -119 | -230 |
| Working Capital Days | 146 | 21 | 75 | -75 | -497 | -643 |
| ROCE % | — | -18 | -11 | -23 | -78 | -108 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 16.86 | Sell |
| EMA (10) | 16.74 | Sell |
| SMA (20) | 17.47 | Sell |
| EMA (20) | 17.43 | Sell |
| SMA (50) | 19.11 | Sell |
| EMA (50) | 18.82 | Sell |
| SMA (100) | 19.88 | Sell |
| EMA (100) | 20.83 | Sell |
| SMA (200) | 26.02 | Sell |
| EMA (200) | 24.09 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 33.75 | Neutral |
| MACD (12,26,9) | -0.88 | Sell |
| Stochastic (14,3,3) | 30.46 | Neutral |
| ADX (14) | 47.1 | Buy |
| Williams %R (14) | -78.09 | Neutral |
| ATR (14) | 1.4 | High Volatility |
| ROC (12) | -9.18 | Sell |
| Stoch RSI (14) | 22.13 | Neutral |
| UO (7,14,28) | 43.58 | Neutral |

## Filings & Documents

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_KOPDRUGS_2010_2011_21092011110505.zip) |
| from nse | [Annual Report 2010 from nse](https://archives.nseindia.com/annual_reports/AR_KOPDRUGS_2008_2010_18082010121500.zip) |
| from bse | [Annual Report 2012 from bse](https://www.bseindia.com/bseplus/AnnualReport/532291/5322910312.PDF) |
| from bse | [Annual Report 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport/532291/5322910311.pdf) |
| from bse | [Annual Report 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport/532291/5322910310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:40:16.954Z.